Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal ...

Recurrent Clostridium difficile (C diff) infection is a hard-to-treat gastrointestinal (GI) infection that causes 29,000 deaths every year in the US alone. Microbiome drug gets Breakthrough ...

diff to participate in a clinical trial. FMT offers hope to patients suffering from recurrent C. diff infection, as a safe and effective treatment. The majority of patients with recurrent C.

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Standard antibiotic treatment clears most infections ... CDI can also result in significant health complications. People with ...

FDA approved to prevent recurrent C. difficile infection (rCDI ... Home to help patients with rCDI across the U.S. receive treatment at home as well as health care settings Ferring continues ...

Although this treatment is relatively new it has ... NICE have found that the evidence supporting FMT for recurrent Clostridium difficile infection is sufficient for the procedure to be carried ...